Table 1.
ATP citrate lyase expression according to IHC score.
| ATP Citrate Lyase | p-Value | ||
|---|---|---|---|
| Negative (n = 203) | Positive (n = 187) | ||
| Age (years), median (IQR) | 71.0 (65.0–77.0) | 68.0 (63.0–72.0) | <0.01 |
| PSA (ng/mL), median IQR) | 5.7 (2.11–8.9) | 7.57 (5.6–11.5) | <0.01 |
| Fasting glucose (mg/dL), median (IQR) | 98.0 (88.0–111.0) | 95.0 (87.0–108.5) | 0.23 |
| Total cholesterol (mg/dL), median (IQR) | 183.0 (157.0–210.0 | 190.5 (159.0–216.0) | 0.38 |
| Triglycerides (mg/dL), median (IQR) | 100.0 (65.0–150.0) | 101.5 (73.0–136.0) | 0.84 |
| Diabetes, n (%) | 28 (26.92) | 44 (15.38) | <0.01 |
| Group, n (%) | <0.01 | ||
| BPH | 86 (42.36) | 18 (9.63) | |
| PC | 117 (57.64) | 169 (90.37) | |
| ISUP Gleason score, n (%) | 0.21 | ||
| 1 | 35 (29.91) | 47 (27.81) | |
| 2 | 52 (44.44) | 58 (34.32) | |
| 3 | 22 (18.80) | 44 (26.04) | |
| 4 | 3 (2.56) | 11 (6.51) | |
| 5 | 5 (4.27) | 9 (5.33) | |
| Pathological stage, n (%) | 0.55 | ||
| T2 | 84 (71.79) | 113 (66.86) | |
| T3 | 21 (17.95) | 32 (19.05) | |
| T4 | 12 (10.26) | 24 (14.29) | |
| Classification risk of PC, n (%) | 0.57 | ||
| Low risk | 42 (35.90) | 58 (34.32) | |
| Intermediate risk | 54 (46.15) | 72 (42.60) | |
| High risk | 21 (17.95) | 39 (23.08) | |
| Ki-67 positive score, n (%) | 20 (9.85) | 33 (17.65) | 0.02 |
| AR positive score, n (%) | 84 (41.38) | 98 (52.41) | 0.03 |
| PSMA positive score, n (%) | 58 (28.57) | 90 (48.13) | <0.01 |
| IR-α positive score, n (%) | 105 (51.72) | 154 (82.35) | <0.01 |
| IR-β positive score, n (%) | 9 (4.43) | 14 (7.49) | 0.20 |
| IGF-1R positive score, n (%) | 23 (11.33) | 41 (21.93) | <0.01 |
| SRSF-1 positive score, n (%) | 80 (39.41) | 108 (57.75) | <0.01 |
| CPT1-a positive score, n (%) | 30 (14.78) | 35 (18.72) | 0.30 |
| SCD-1 positive score, n (%) | 24 (11.82) | 41 (21.93) | <0.01 |
| SREBP1 positive score, n (%) | 39 (19.21) | 57 (30.48) | 0.01 |
| FAS positive score, n (%) | 68 (33.50) | 144 (77.01) | <0.01 |
| ACC-1 positive score, n (%) | 31 (15.27) | 113 (60.43) | <0.01 |
IRS = immunoreactivity score BPH = Benign Prostatic Hyperplasia; PCa = prostate cancer; IQR = interquartile range; AR = Androgenic receptor; IR = insulin receptor; IGF-1R = insulin-like growth factor-1 receptor; PSMA = prostate specific membrane antigen; SRSF-1 = Serine/arginine-rich splicing factor 1; FAS = fatty acid synthase; CPT-1a = Carnitine palmitoyltransferase 1a; SCD-1 = Stearoyl-CoA desaturase-1; SREBP-1 = Sterol regulatory element-binding protein-1; AC-1 = Acetyl-CoA Carboxylase-1.